Aura Biosciences Inc
AURA5.990USD
-0.030-0.50%
Market hours （ET）Quotes delayed by 15 min
377.28MMarket Cap
LossP/E TTM
More Details of Aura Biosciences Inc Company
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Aura Biosciences Inc Info
Ticker SymbolAURA
Company nameAura Biosciences Inc
IPO dateOct 29, 2021
CEODe Los Pinos (Elisabet)
Number of employees106
Security typeOrdinary Share
Fiscal year-endOct 29
Address80 Guest Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02135
Phone16175008864
Websitehttps://aurabiosciences.com/
Ticker SymbolAURA
IPO dateOct 29, 2021
CEODe Los Pinos (Elisabet)
Company Executives of Aura Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Plavsic, Ph.D.
Dr. Mark Plavsic, Ph.D.
Chief Technology Officer
Chief Technology Officer
197.29K
-5.81%
Ms. Amy Elazzouzi
Ms. Amy Elazzouzi
Senior Vice President - Finance
Senior Vice President - Finance
85.66K
-1.04%
Ms. Teresa Marie Bitetti
Ms. Teresa Marie Bitetti
Independent Director
Independent Director
21.00K
--
Mr. Conor Kilroy, J.D.
Mr. Conor Kilroy, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
16.84K
-29.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
13.00K
--
Mr. Antony Charles Mattessich
Mr. Antony Charles Mattessich
Independent Director
Independent Director
13.00K
--
Dr. Elisabet (Eli) De Los Pinos, Ph.D.
Dr. Elisabet (Eli) De Los Pinos, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Dr. Giovanni Mariggi, Ph.D.
Dr. Giovanni Mariggi, Ph.D.
Independent Director
Independent Director
--
--
Dr. J. Jill Hopkins, M.D.
Dr. J. Jill Hopkins, M.D.
Chief Medical Officer and President of Research & Development
Chief Medical Officer and President of Research & Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Plavsic, Ph.D.
Dr. Mark Plavsic, Ph.D.
Chief Technology Officer
Chief Technology Officer
197.29K
-5.81%
Ms. Amy Elazzouzi
Ms. Amy Elazzouzi
Senior Vice President - Finance
Senior Vice President - Finance
85.66K
-1.04%
Ms. Teresa Marie Bitetti
Ms. Teresa Marie Bitetti
Independent Director
Independent Director
21.00K
--
Mr. Conor Kilroy, J.D.
Mr. Conor Kilroy, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
16.84K
-29.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
13.00K
--
Mr. Antony Charles Mattessich
Mr. Antony Charles Mattessich
Independent Director
Independent Director
13.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Matrix Capital Management Company, LP
10.90%
Frazier Life Sciences Management, L.P.
8.03%
Adage Capital Management, L.P.
7.69%
Long Focus Capital Management LLC
7.27%
Suvretta Capital Management, LLC
6.89%
Other
59.22%
Shareholders
Shareholders
Proportion
Matrix Capital Management Company, LP
10.90%
Frazier Life Sciences Management, L.P.
8.03%
Adage Capital Management, L.P.
7.69%
Long Focus Capital Management LLC
7.27%
Suvretta Capital Management, LLC
6.89%
Other
59.22%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.31%
Investment Advisor/Hedge Fund
23.17%
Investment Advisor
16.94%
Venture Capital
9.31%
Private Equity
8.03%
Individual Investor
1.96%
Research Firm
0.59%
Bank and Trust
0.08%
Pension Fund
0.02%
Other
13.58%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
211
53.71M
92.47%
+3.75K
2025Q3
218
53.71M
94.44%
+1.07M
2025Q2
211
52.63M
87.69%
+5.36M
2025Q1
194
41.84M
87.54%
-2.13M
2024Q4
187
41.40M
83.19%
+2.64M
2024Q3
167
38.74M
89.45%
-3.01M
2024Q2
159
41.74M
87.61%
+474.27K
2024Q1
151
41.25M
82.55%
+388.11K
2023Q4
140
39.11M
70.86%
+5.19M
2023Q3
126
31.61M
83.76%
+426.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Matrix Capital Management Company, LP
6.92M
11.14%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
5.10M
8.21%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
4.88M
7.86%
--
--
Jun 30, 2025
Long Focus Capital Management LLC
4.62M
7.44%
+1.30M
+39.16%
Jun 30, 2025
Suvretta Capital Management, LLC
4.37M
7.04%
+1.32M
+43.03%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.77M
4.45%
-423.56K
-13.28%
Jun 30, 2025
Medicxi Ventures (UK) LLP
3.04M
4.89%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.48M
3.99%
+525.17K
+26.90%
Jun 30, 2025
Franklin Advisers, Inc.
2.34M
3.77%
+130.01K
+5.88%
Jun 30, 2025
Nantahala Capital Management, LLC
2.12M
3.41%
+850.00K
+67.05%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AltShares Event-Driven ETF
0.88%
Harbor Human Capital Factor US Small Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.05%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
AltShares Event-Driven ETF
Proportion0.88%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aura Biosciences Inc?
The top five shareholders of Aura Biosciences Inc are:
Matrix Capital Management Company, LP holds 6.92M shares, accounting for 11.14% of the total shares.
Frazier Life Sciences Management, L.P. holds 5.10M shares, accounting for 8.21% of the total shares.
Adage Capital Management, L.P. holds 4.88M shares, accounting for 7.86% of the total shares.
Long Focus Capital Management LLC holds 4.62M shares, accounting for 7.44% of the total shares.
Suvretta Capital Management, LLC holds 4.37M shares, accounting for 7.04% of the total shares.
Matrix Capital Management Company, LP holds 6.92M shares, accounting for 11.14% of the total shares.
Frazier Life Sciences Management, L.P. holds 5.10M shares, accounting for 8.21% of the total shares.
Adage Capital Management, L.P. holds 4.88M shares, accounting for 7.86% of the total shares.
Long Focus Capital Management LLC holds 4.62M shares, accounting for 7.44% of the total shares.
Suvretta Capital Management, LLC holds 4.37M shares, accounting for 7.04% of the total shares.
What are the top three shareholder types of Aura Biosciences Inc?
The top three shareholder types of Aura Biosciences Inc are:
Matrix Capital Management Company, LP
Frazier Life Sciences Management, L.P.
Adage Capital Management, L.P.
Matrix Capital Management Company, LP
Frazier Life Sciences Management, L.P.
Adage Capital Management, L.P.
How many institutions hold shares of Aura Biosciences Inc (AURA)?
As of 2025Q4, 211 institutions hold shares of Aura Biosciences Inc, with a combined market value of approximately 53.71M, accounting for 92.47% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.97%.
What is the biggest source of revenue for Aura Biosciences Inc?
In --, the -- business generated the highest revenue for Aura Biosciences Inc, amounting to -- and accounting for --% of total revenue.
